S&P 500   4,034.13 (+1.93%)
DOW   34,251.05 (+1.18%)
QQQ   289.07 (+3.03%)
AAPL   145.79 (+3.27%)
MSFT   249.64 (+3.87%)
META   116.43 (+6.37%)
GOOGL   99.33 (+4.35%)
AMZN   94.32 (+2.06%)
TSLA   188.56 (+4.27%)
NVDA   163.87 (+4.78%)
NIO   12.60 (+20.00%)
BABA   88.58 (+10.92%)
AMD   76.14 (+3.75%)
T   19.03 (+0.11%)
MU   56.76 (+2.98%)
CGC   3.52 (+2.92%)
F   13.75 (+0.00%)
GE   85.65 (-0.01%)
DIS   96.49 (+1.90%)
AMC   7.23 (-2.69%)
PYPL   78.08 (+0.57%)
PFE   49.48 (-0.02%)
NFLX   303.40 (+7.99%)
S&P 500   4,034.13 (+1.93%)
DOW   34,251.05 (+1.18%)
QQQ   289.07 (+3.03%)
AAPL   145.79 (+3.27%)
MSFT   249.64 (+3.87%)
META   116.43 (+6.37%)
GOOGL   99.33 (+4.35%)
AMZN   94.32 (+2.06%)
TSLA   188.56 (+4.27%)
NVDA   163.87 (+4.78%)
NIO   12.60 (+20.00%)
BABA   88.58 (+10.92%)
AMD   76.14 (+3.75%)
T   19.03 (+0.11%)
MU   56.76 (+2.98%)
CGC   3.52 (+2.92%)
F   13.75 (+0.00%)
GE   85.65 (-0.01%)
DIS   96.49 (+1.90%)
AMC   7.23 (-2.69%)
PYPL   78.08 (+0.57%)
PFE   49.48 (-0.02%)
NFLX   303.40 (+7.99%)
S&P 500   4,034.13 (+1.93%)
DOW   34,251.05 (+1.18%)
QQQ   289.07 (+3.03%)
AAPL   145.79 (+3.27%)
MSFT   249.64 (+3.87%)
META   116.43 (+6.37%)
GOOGL   99.33 (+4.35%)
AMZN   94.32 (+2.06%)
TSLA   188.56 (+4.27%)
NVDA   163.87 (+4.78%)
NIO   12.60 (+20.00%)
BABA   88.58 (+10.92%)
AMD   76.14 (+3.75%)
T   19.03 (+0.11%)
MU   56.76 (+2.98%)
CGC   3.52 (+2.92%)
F   13.75 (+0.00%)
GE   85.65 (-0.01%)
DIS   96.49 (+1.90%)
AMC   7.23 (-2.69%)
PYPL   78.08 (+0.57%)
PFE   49.48 (-0.02%)
NFLX   303.40 (+7.99%)
S&P 500   4,034.13 (+1.93%)
DOW   34,251.05 (+1.18%)
QQQ   289.07 (+3.03%)
AAPL   145.79 (+3.27%)
MSFT   249.64 (+3.87%)
META   116.43 (+6.37%)
GOOGL   99.33 (+4.35%)
AMZN   94.32 (+2.06%)
TSLA   188.56 (+4.27%)
NVDA   163.87 (+4.78%)
NIO   12.60 (+20.00%)
BABA   88.58 (+10.92%)
AMD   76.14 (+3.75%)
T   19.03 (+0.11%)
MU   56.76 (+2.98%)
CGC   3.52 (+2.92%)
F   13.75 (+0.00%)
GE   85.65 (-0.01%)
DIS   96.49 (+1.90%)
AMC   7.23 (-2.69%)
PYPL   78.08 (+0.57%)
PFE   49.48 (-0.02%)
NFLX   303.40 (+7.99%)
NASDAQ:LXRX

Lexicon Pharmaceuticals - LXRX Stock Forecast, Price & News

$2.12
+0.07 (+3.41%)
(As of 11/30/2022 02:45 PM ET)
Add
Compare
Today's Range
$2.02
$2.13
50-Day Range
$1.89
$2.56
52-Week Range
$1.31
$4.87
Volume
13,997 shs
Average Volume
343,956 shs
Market Capitalization
$400.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Lexicon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
621.2% Upside
$15.00 Price Target
Short Interest
Healthy
2.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.38mentions of Lexicon Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.60) to ($0.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

806th out of 1,043 stocks

Pharmaceutical Preparations Industry

392nd out of 510 stocks

LXRX stock logo

About Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Stock News Headlines

StockNews.com Lowers Lexicon Pharmaceuticals (NASDAQ:LXRX) to Sell
Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded at StockNews.com
Lexicon Pharmaceuticals (LXRX) Gets a Hold from Needham
Lexicon Pharmaceuticals, Inc. (LXRX)
See More Headlines
Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Company Calendar

Last Earnings
11/03/2021
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LXRX
Previous Symbol
NASDAQ:LEXG
CUSIP
52887210
Employees
87
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+371.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-87,760,000.00
Net Margins
-77,648.80%
Pretax Margin
-77,648.80%

Debt

Sales & Book Value

Annual Sales
$300,000.00
Book Value
$0.76 per share

Miscellaneous

Free Float
176,459,000
Market Cap
$400.11 million
Optionable
Optionable
Beta
1.36

Social Links


Key Executives

  • Mr. Lonnel Coats (Age 57)
    CEO & Director
    Comp: $1.14M
  • Mr. Jeffrey L. Wade J.D. (Age 57)
    Pres & CFO
    Comp: $718.14k
  • Mr. Brian T. Crum (Age 49)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $557.49k
  • Dr. Alan J. Main Ph.D. (Age 68)
    Exec. VP of Innovation & Chemical Sciences
    Comp: $574.2k
  • Dr. Craig B. Granowitz M.D. (Age 57)
    Ph.D., Sr. VP & Chief Medical Officer
    Comp: $450.46k
  • Dr. Robert J. Lefkowitz M.D. (Age 78)
    Consultant & Independent Director
    Comp: $50k
  • Ms. Kristen L. Alexander (Age 54)
    VP of Fin. & Accounting
  • Chas Schultz
    Exec. Director of Corp. Communications & Patient Advocacy
  • Ms. Wendy E. McDermott (Age 51)
    VP of HR
  • Dr. Kenneth B. Kassler-Taub M.D. (Age 66)
    Sr. VP of Regulatory Affairs & Quality Assurance













LXRX Stock - Frequently Asked Questions

Should I buy or sell Lexicon Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LXRX shares.
View LXRX analyst ratings
or view top-rated stocks.

What is Lexicon Pharmaceuticals' stock price forecast for 2023?

2 equities research analysts have issued 12-month price targets for Lexicon Pharmaceuticals' shares. Their LXRX share price forecasts range from $10.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 604.2% from the stock's current price.
View analysts price targets for LXRX
or view top-rated stocks among Wall Street analysts.

How have LXRX shares performed in 2022?

Lexicon Pharmaceuticals' stock was trading at $3.94 at the beginning of the year. Since then, LXRX shares have decreased by 45.9% and is now trading at $2.13.
View the best growth stocks for 2022 here
.

When is Lexicon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our LXRX earnings forecast
.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The biopharmaceutical company had revenue of $0.02 million for the quarter. Lexicon Pharmaceuticals had a negative net margin of 77,648.80% and a negative trailing twelve-month return on equity of 92.19%. During the same quarter in the prior year, the firm earned $0.71 EPS.

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BVF Inc. IL (8.56%), BlackRock Inc. (3.05%), Vanguard Group Inc. (2.79%), Point72 Asset Management L.P. (1.91%), Pinnacle Associates Ltd. (1.11%) and State Street Corp (0.78%). Insiders that own company stock include International SCA Artal and James F Tessmer.
View institutional ownership trends
.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $2.13.

How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $401.99 million and generates $300,000.00 in revenue each year. The biopharmaceutical company earns $-87,760,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010.

This page (NASDAQ:LXRX) was last updated on 11/30/2022 by MarketBeat.com Staff